Anticancer therapy with novel tubulin-interacting drugs

Drug Resistance Updates

Volumn 4, Issue 6, 2001, Pages 392-401

  Kavallaris, Maria ^a   Verrills, Nicole M ^a,b   Hill, Bridget T ^c  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AURISTATIN PE; BMS 184476; BMS 185660; BMS 188797; BMS 275183; CRYPTOPHYCIN 52; CRYPTOPHYCIN 55; CRYPTOPHYCIN DERIVATIVE; DISCODERMOLIDE; DOLASTATIN; DOLASTATIN 10; EPOTHILONE DERIVATIVE; FR 182877; NAVELBINE; ORTATAXEL; PACLITAXEL; PACLITAXEL POLIGLUMEX; PNU 166945; RHIZOXIN; RPR 109881A; TAXANE DERIVATIVE; TAXOPREXIN; TUBULIN; TXD 258; UNCLASSIFIED DRUG; VINCA ALKALOID; VINFLUNINE;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOMA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW;

EID: 0035744348     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2002.0230     Document Type: Review

References (111)

1. Biochemistry of multidrug resistance mediated by the multidrug transporter
2. The role of Multidrug Resistance-associated Protein (MRP) gene expression in drug resistance
3. A family of drug transporters: The multidrug resistance-associated proteins
4. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
5. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes
6. Factors determining cellular mechanisms of resistance to antimitotic drugs
7. The role of β-tubulin isotypes in resistance to antimitotic drugs
8. Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukaemia cells
9. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization
10. A β-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance
11. Mutations in β-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines
12. Taxol stabilizes microtubules in mouse fibroblast cells
13. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations
14. Substoichiometric binding of taxol suppresses microtubule dynamics
15. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules
16. Modifications in the "upper" velbenamine part of the vinca alkaloids have major implications for tubulin interacting activities
17. Antimicrotubule agents
18. Vinflunine, the latest vinca alkaloid in clinical development. A review of its preclinical anticancer properties
19. Vinflunine, a second generation novel vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers
20. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic vinca alkaloids vinorelbine and its newer derivative vinflunine
21. How do the newer vinca alkaloids vinflunine and vinorelbine block mitosis? Effects on centromere movements in living mitotic U20s cells
22. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
23. Significant antianglogenic activity and marked inhibition of growth of an orthotopic colon cancer model and colon cancer liver metastases by vinflunine, the most recent vinca alkaloid in clinical development
24. Markedly diminished drug-resistance inducing properties of vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro, with clinical implications
25. Antiproliferative mechanisms of action of cryptophycin-52: Kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends
26. Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells
27. Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumour xenografts
28. Antitumour activity of cryptophycins: Effect of infusion time and combination studies
29. Cryptophycins: A novel class of potent antitumor depsipeptides
30. Interaction of dolastatin 10 with tubulin: Induction of aggregation and binding and dissociation reactions
31. Phase 1 trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors
32. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma
33. Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the California Cancer Consortium
34. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death
35. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin
36. An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models
37. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity
38. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors
39. New antimitotic agents with activity in multi-drug resistant cell lines and in vivo efficacy in murine tumor models
40. Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumour agent from taxus brevifolia
41. Mechanism of action of taxol
42. Structure of the αβ tubulin dimer by electron crystallography
43. High resolution model of the microtubule
44. How Taxol stabilises microtubule structure
45. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule stability
46. Pharmacology and toxicology of cremophor EL diluent
47. Docetaxel (Taxotere): An effective agent in the management of second-line breast cancer
48. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents
49. Preclinical evaluation of new taxoids
50. Phase 1 and Pharmacokinetic Study of RPR116258A, a Novel Taxane Derivative, Administered Intravenously over 1 Hour Every 3 Weeks
51. Phase 1 and pharmacokinetic study of a new taxoid, RPR 109881 A, given as a 1-hour intravenous infusion in patients with advanced solid tumors
52. Preclinical antitumor activity of two novel taxanes
53. A phase 1 and pharmacokinetic (PK) study of the novel taxane BMS 184476 administered As a 1-hour intravenous (IV) infusion weekly
54. Phase 1 Study of BMS-188797, a New Taxane Analog, Given Weekly in Patients with Advanced Malignancies
55. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative
56. IDN5109, a taxane with oral bioavailability and potent antitumor activity
57. Epothilons A and B: Antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties
58. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action
59. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R))
60. Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity
61. Synthesis of epothilones A and B in solid and solution phase
62. Synthesis and biological properties of C 12,13-cyclopropyl-epothilone A and related epothilones
63. Total syntheses of epothilones B and D
64. Epothilones and related structures - A new class of microtubule inhibitors with potent in vivo antitumor activity
65. On the total synthesis and preliminary biological evaluations of 15(R) and 15(S) aza-dEpoB: A Mitsunobu inversion at C 15 in pre-epothilone fragments
66. A common pharmacophore for cytotoxic natural products that stabilize microtubules
67. A common pharmacophore for Taxol and the epothilones based on the biological activity of a taxane molecule lacking a C-13 side chain
68. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells
69. Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B
70. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel
71. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy
72. Clinical trials referral resource. Current clinical trials of epothilone B analog (BMS-247550)
73. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice
74. The coral-derived natural products eleutherobin and sarcodictyins A and B: Effects on the assembly of purified tubulin with and without microtubule associated proteins and binding at the polymer taxoid site
75. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol)
76. Total synthesis and chemical biology of the sarcodictyins
77. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents
78. Discodermolide - A new, marine-derived immunosuppressive compound. I. In vitro studies
79. Immunosuppression by discodermolide
80. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol
81. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest
82. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells
83. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines
84. Gram-scale synthesis of (+)-discodermolide
85. A practical synthesis of (+)-discodermolide and analogues: Fragment union by complex aldol reactions
86. Acetylated analogues of the microtubule-stabilizing agent discodermolide: Preparation and biological activity
87. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial
88. Phase 1 study of liposomal vincristine
89. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model
90. Past and future of the mitotic spindle as an oncology target
91. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel
92. Tumor targeting by conjugation of DHA to paclitaxel
93. Technology evaluation: C242-DMI, ImmunoGen Inc
94. Phase 1 and pharmacological study of CT-2103, a poly (L-glutamic Acid)-paclitaxel conjugate
95. A novel oral taxane (BMS-275183): A phase 1 trial with evaluation of pharmacokinetics, pharmacodynamics and bioavailability
96. Dissecting cellular processes using small molecules: Identification of colchicine-like, taxol-like and other small molecules that perturb mitosis
97. A phase 1 study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors
98. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: Exceptional activity against drug-resistant cancer cells
99. Preclinical pharmacology of BMS-275183, an orally active taxane
100. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate
101. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-tumor
102. Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cell
103. An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel
104. Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel
105. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers
106. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors
107. Phase 1 clinical and pharmacokinetic study of PNU 166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel
108. A new antimitotic substance, FR 182877. II. The mechanism of action
109. A new antimitotic substance, FR182877. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities
110. The relevance of drug sequence in combination chemotherapy
111. Does P-glycoprotein play a role in anticancer drug pharmacokinetics?